Research ArticleAutoimmunity

The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study

See allHide authors and affiliations

Science Translational Medicine  01 Nov 2017:
Vol. 9, Issue 414, eaan1208
DOI: 10.1126/scitranslmed.aan1208

The benefits of not recycling

Autoimmune diseases mediated by pathogenic IgG can be treated by B cell–depleting therapies or IVIg, but such therapies are costly and not without side effects. IgG is recycled and kept in the circulation partially through the activity of the neonatal Fc receptor (FcRn). Kiessling et al. report the development of a monoclonal antibody to inhibit FcRn, which should lower IgG levels, thereby reducing pathogenic IgG. This antibody was tested for safety and efficacy in nonhuman primates as well as humans. The antibody was well-tolerated and substantially reduced circulating IgG. These promising results warrant further testing in autoimmune individuals.

View Full Text

Stay Connected to Science Translational Medicine